Company: SMNR
Filing Date: 2025-08-13
Form Type: 424B3
Source: 0001193125-25-179226
Chunk: 33

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-13
Form: 424B3
Chunk 33
---
,” “could,” “may,” “might,” “possible,” “potential,” “predict,” “should,” “would” and other similar words and expressions, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on information available as of the date of this proxy statement/prospectus and Denali’s and Semnur’s managements’ current expectations, forecasts and assumptions, and involve a number of judgments, known and unknown risks and uncertainties and other factors, many of which are outside the control of Denali, Semnur and their respective directors, officers and affiliates. There can be no assurance that future developments will be those that have been anticipated. Accordingly, forward-looking statements should not be relied upon as representing Denali’s views as of any subsequent date. Denali does not undertake any obligation to update, add or to otherwise correct any forward-lookingstatements contained herein to reflect events or circumstances after the date they were made, whether as a result of new information, future events, inaccuracies that become apparent after the date hereof or otherwise, except as may be required under applicable securities laws. You should not place undue reliance on these forward-looking statements in deciding how your vote should be cast or in voting your Denali Ordinary Shares on the Proposals. These forward-looking statements involve a number of risks, uncertainties or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in “ Risk Factors,” those discussed and identified in public filings made with the SEC by Denali and the following:

| • |     | our ability to complete the Business Combination with Semnur or, if we do not consummate such Business 
 Combination, any other initial business combination;                                                   |

| • |     | satisfaction or waiver (if applicable) of the conditions to the consummation of the Business Combination, 
 including the approval of the Merger Agreement by the shareholders of Denali;                             |

| • |     | the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger 
 Agreement;                                                                                                       |

| • |     | the projected financial information, including Semnur’s forecasts (included in the section titled                                                                  
 “Proposal 1 — The Business Combination Proposal — Certain Semnur Projected Financial Information”), anticipated growth rate, and market opportunity of New Semnur; |

| • |